company background image
A950210 logo

Prestige BioPharma KOSE:A950210 Stock Report

Last Price

₩14.54k

Market Cap

₩179.1b

7D

-3.3%

1Y

53.4%

Updated

26 Dec, 2024

Data

Company Financials

Prestige BioPharma Limited

KOSE:A950210 Stock Report

Market Cap: ₩179.1b

A950210 Stock Overview

A biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. More details

A950210 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Prestige BioPharma Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Prestige BioPharma
Historical stock prices
Current Share Price₩14,540.00
52 Week High₩20,900.00
52 Week Low₩7,610.00
Beta1.14
1 Month Change0.83%
3 Month Change4.01%
1 Year Change53.38%
3 Year Change-30.26%
5 Year Changen/a
Change since IPO-55.67%

Recent News & Updates

Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

Oct 23
Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

Recent updates

Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

Oct 23
Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

Shareholder Returns

A950210KR BiotechsKR Market
7D-3.3%-2.3%-1.9%
1Y53.4%14.9%-9.5%

Return vs Industry: A950210 exceeded the KR Biotechs industry which returned 14.9% over the past year.

Return vs Market: A950210 exceeded the KR Market which returned -9.5% over the past year.

Price Volatility

Is A950210's price volatile compared to industry and market?
A950210 volatility
A950210 Average Weekly Movement10.8%
Biotechs Industry Average Movement8.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.8%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A950210's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A950210's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aSo-Yeon Parkwww.prestigebiopharma.com

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.

Prestige BioPharma Limited Fundamentals Summary

How do Prestige BioPharma's earnings and revenue compare to its market cap?
A950210 fundamental statistics
Market cap₩179.09b
Earnings (TTM)-₩29.59b
Revenue (TTM)₩2.84b

61.5x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A950210 income statement (TTM)
Revenue₩2.84b
Cost of Revenue₩1.22b
Gross Profit₩1.63b
Other Expenses₩31.22b
Earnings-₩29.59b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.46k
Gross Margin57.17%
Net Profit Margin-1,040.78%
Debt/Equity Ratio22.2%

How did A950210 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:53
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prestige BioPharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Junghyun KimKyobo Securities Co., Ltd
Keunhee SeoSamsung Securities Co. Ltd.